Investors & News

Investor Relations

Webcast ImageWebcast
Q4 2016 Ascendis Pharma Earnings Conference Call (Replay)
03/22/17 at 4:30 p.m. ET
Q4 2016 Ascendis Pharma Earnings Conference Call
Wednesday, March 22, 2017 4:30 p.m. ET  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar
Webcast ImageWebcast
Ascendis Pharma ENDO Data Review (Live)
04/03/17 at 4:30 p.m. ET
Ascendis Pharma ENDO Data Review
Monday, April 3, 2017 4:30 p.m. ET  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar

Ascendis Pharma is a clinical stage biopharmaceutical company applying its TransCon technology to develop a pipeline of long-acting prodrug therapies with best-in-class profiles to address large markets with significant unmet medical needs.

Stock Information
ASND (Common Stock)
ExchangeNASDAQ GS (US Dollar)
Price$27.49
Change (%) Stock is Up 0.04 (0.15%)
Volume43,905
Data as of 03/28/17 4:00 p.m. ET
Refresh quote
Stock chart for: ASND.O.  Currently trading at $27.49 with a 52 week high of $30.57 and a 52 week low of $11.92.
Recent NewsMore >>
23/Mar/2017
Ascendis Pharma A/S Announces Conference Call and Webcast to Review Data at ENDO 2017 on April 3
22/Mar/2017
Ascendis Pharma A/S Reports Full Year 2016 Financial Results
10/Mar/2017
Ascendis Pharma A/S Announces Year-End 2016 Financial Results Conference Call on March 22
Upcoming EventsMore >>
Ascendis Pharma ENDO Data Review
Monday, April 3, 2017 4:30 p.m. ET
Primary IR Contact
Scott T. Smith
Chief Financial Officer
Ascendis Pharma
E-mail: ir@ascendispharma.com

Data provided by Nasdaq. Minimum 15 minutes delayed.